Scott Gottlieb, MD: The ACA and the BPCIA

Video

Scott Gottlieb, MD, former commissioner of the FDA, discusses what might become of the Biologics Price Competition and Innovation Act (BPCIA) if the Affordable Care Act (ACA) is invalidated.

Transcript

We’ll see what the courts ultimately do. I’m pretty confident that Congress would continue to authorize the biosimilar pathway, and if for some reason the Affordable Care Act was struck—which doesn’t seem likely—but if for some reason it was struck, I think Congress would come back in and quickly reauthorize the biosimilar pathway.

Related Videos
Ha Kung Wong, JD.
Ha Kung Wong, JD
Cencora's Corey Ford
Brian Biehn
Chelsee Jensen, PharmD, BCPS
Ryan Haumschild, PharmD, MS, MBA
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD
Fran Gregory, PharmD, MBA
Related Content
© 2024 MJH Life Sciences

All rights reserved.